Lymphoma
Non-Hodgkin lymphoma (NHL) is one of the most common hematologic malignancies worldwide. The incidence of NHL has been rising for several decades; NHL incidence among males is significantly higher than in females
Lymphoma makes up a heterogeneous group of neoplastic diseases of lymphocytes origin. These malignant lymphoproliferative processes are clonal B-cell, T-cell or natural killer (NK) cells tumors in different stages of differentiation. Lymphomas represent 6% of all neoplasms and are responsible for 3% of the mortality by oncological processes. The incidence of lymphomas is up to 4% each year, with around 6000 new cases being diagnosed annually. Lymphomas are somewhat more frequent in men than in women and more common in 2 age groups: from 15 to 40 years of age (being more frequent between 25 and 30 years) and after the age of 55 years. There are important differences among the principal types of lymphoma
Lymphoma is generally divided into two groups: Hodgkin’s disease (HD) and an inhomogeneous group of conditions called non-Hodgkin’s lymphoma (NHL). HD tends to involve a single nodal group and spread in a fixed pattern along the lymphatic chain, with infrequent extra lymph node involvement. NHL is a multifocal disease which often presents late with disseminated extranodal spread
One of the most evident advantages of FDG-PET was its ability to detect significant changes in glucose metabolism or even complete remission. This enables clinicians to detect much earlier the effectiveness of a given anti-neoplastic treatment, as compared to the traditional CT imaging alone
One of the most challenging aspects in the imaging of lymphomas is the assessment of response to treatment. Differentiation of tumor from fibrosis within residual radiographic masses represents a problem of interpretation for non-Hodgkin’s lymphoma. Thus accurate staging is the basis for the selection of an appropriate therapeutic approach, in order to prevent over or under treatment as well as to minimize morbidity related to the radio-chemotherapy regimens given
Quality of life during and after treatment may also be improved when therapy is tailored appropriately. So that Positron emission tomography (PET) scan with the glucose analogue 2-(F-18)-fluoro-2-deoxy- D-glucose (18F-FDG) has emerged as a clinical method for staging and monitoring responses to treatment
Antoch , Freudenberg , Stattaus et al. Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR. 2002;179:1555–1560.
Awan UE, Siddiqui N, SaadUllah M, et al. FDG-PET scan in assessing lymphomas and the application of Deauville Criteria.J Pak Med Assoc. 2013;63(6):725-30.
Au Yong TK, Wong CP, Leung YK, Chu KS, et al.Evaluation of positron emission tomography in the diagnosis of primary tumors in patients presenting with
Non-Hodgkin lymphoma (NHL) is one of the most common hematologic malignancies worldwide. The incidence of NHL has been rising for several decades; NHL incidence among males is significantly higher than in females
Lymphoma makes up a heterogeneous group of neoplastic diseases of lymphocytes origin. These malignant lymphoproliferative processes are clonal B-cell, T-cell or natural killer (NK) cells tumors in different stages of differentiation. Lymphomas represent 6% of all neoplasms and are responsible for 3% of the mortality by oncological processes. The incidence of lymphomas is up to 4% each year, with around 6000 new cases being diagnosed annually. Lymphomas are somewhat more frequent in men than in women and more common in 2 age groups: from 15 to 40 years of age (being more frequent between 25 and 30 years) and after the age of 55 years. There are important differences among the principal types of lymphoma
Lymphoma is generally divided into two groups: Hodgkin’s disease (HD) and an inhomogeneous group of conditions called non-Hodgkin’s lymphoma (NHL). HD tends to involve a single nodal group and spread in a fixed pattern along the lymphatic chain, with infrequent extra lymph node involvement. NHL is a multifocal disease which often presents late with disseminated extranodal spread
One of the most evident advantages of FDG-PET was its ability to detect significant changes in glucose metabolism or even complete remission. This enables clinicians to detect much earlier the effectiveness of a given anti-neoplastic treatment, as compared to the traditional CT imaging alone
One of the most challenging aspects in the imaging of lymphomas is the assessment of response to treatment. Differentiation of tumor from fibrosis within residual radiographic masses represents a problem of interpretation for non-Hodgkin’s lymphoma. Thus accurate staging is the basis for the selection of an appropriate therapeutic approach, in order to prevent over or under treatment as well as to minimize morbidity related to the radio-chemotherapy regimens given
Quality of life during and after treatment may also be improved when therapy is tailored appropriately. So that Positron emission tomography (PET) scan with the glucose analogue 2-(F-18)-fluoro-2-deoxy- D-glucose (18F-FDG) has emerged as a clinical method for staging and monitoring responses to treatment
Antoch , Freudenberg , Stattaus et al. Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR. 2002;179:1555–1560.
Awan UE, Siddiqui N, SaadUllah M, et al. FDG-PET scan in assessing lymphomas and the application of Deauville Criteria.J Pak Med Assoc. 2013;63(6):725-30.
Au Yong TK, Wong CP, Leung YK, Chu KS, et al.Evaluation of positron emission tomography in the diagnosis of primary tumors in patients presenting with
0 Comments